Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2007 / Cilt: 41 - Sayı: 3

An adrenal hyperplasia case presenting with hyperparathyroidism and diabetes insipidus

Hiperparatiroidi ve diabetes insipidus ile seyreden idiopatik adrenal hiperplazi olgusu

Pages
45–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this patient hypokalemia caused metabolic alchalosis which resulted a decrease in ionized calcium levels causing secondary hyperparathyroidism and patient also had hypokalemia releated nephrogenic diabetes insipidus.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Causes of primary hyperaldosteronism are aldosteron secreting adenoma, aldosteron secreting carcinoma and bilateral adrenocortical hyperplasia. %25-%35 of adrenocortical hyperplasia patients have idiopathic hyperaldosteronism.
📊
Key Findings & Data:In our case report, we described a patient who had resistant hypokalemia since he was 2 years old.
💡
Conclusion & Impact:In this patient hypokalemia caused metabolic alchalosis which resulted a decrease in ionized calcium levels causing secondary hyperparathyroidism and patient also had hypokalemia releated nephrogenic diabetes insipidus.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Böbrek üstü bezinin hiperplazisi · doğuştan · Diabetes insipidus

Abstract

Causes of primary hyperaldosteronism are aldosteron secreting adenoma, aldosteron secreting carcinoma and bilateral adrenocortical hyperplasia. %25-%35 of adrenocortical hyperplasia patients have idiopathic hyperaldosteronism. In these cases adrenal cortex may be normal, macronodular or micronodular macroscopically, or may be hyperplasic, microscopically. In our case report, we described a patient who had resistant hypokalemia since he was 2 years old. In this patient hypokalemia caused metabolic alchalosis which resulted a decrease in ionized calcium levels causing secondary hyperparathyroidism and patient also had hypokalemia releated nephrogenic diabetes insipidus.

Özet

Primer hiperaldosteronizm nedenleri arasında aldosteron salgılayan adenom, aldosteron salgılayan karsinom ile bilateral adrenokortikal hiperplazi yer almaktadır. Adrenokortikal hiperplazi vakalarının %25-35'ini teşkil eden idiopatik hiperaldosteronizmde adrenal kortekslerin makroskopik olarak normal, veya mikro ve makronodüllü, ya da mikroskopi ile hiperplazik oldukları gösterilmiştir. Biz bu olgu sunumumuzda 2 yaşından itibaren dirençli hipopotasemi tablosuyla seyreden ve bunun neden olduğu metabolik alkaloza bağlı iyonize kalsiyum düşüklüğü sonucu oluşan sekonder hiperparatiroidi ve yine hipopotasemiye bağlı nefrojenik diabetes insipiduslu vakayı irdeledik.

🔖

Cite This Article

ŞENER, N., UÇAK, S., SALER, T., ŞATIR, E., ALTUNTAŞ, Y. (2007). An adrenal hyperplasia case presenting with hyperparathyroidism and diabetes insipidus. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 41 - Sayı: 3, 45–48. https://ajindex.com/articles/363890

References (7)

  1. Stewart PM: Mineralocorticoid hypertension. Lancet 17:1341-7, 1999
  2. Weinberger MH, Fineberg NS: The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 27: 2125-9, 1993
  3. Goodwin KD, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT: Preventing oxidative stres in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci:73-8, 2006
  4. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT: Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 22: 871-8, 2005
  5. Marples D, Fr0kiaer J, D0rup J, Knepper MA, Nielsen S: Hypokalemia induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest 15:1960-8, 1996
  6. Koloğlu: Temel ve Klinik Endokrinoloji 2. baskı, sayfa 62 7. Kaplan NM: Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 737-45, 2006
  7. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, Müller FB, Acevedo R, Ulick S, Laragh Diagnosis and treatment of primary hyperaldosteronism. J.Ann Intern Med 1:877-85, 1994